Abstract Number: 0310 • ACR Convergence 2020
The Prediction of Psoriatic Arthritis Tool (PRESTO) Study – Interim Report
Background/Purpose: A simple, scalable tool that identifies psoriasis patients at high risk for developing PsA could improve early detection and facilitate early intervention. Our overall…Abstract Number: 0695 • ACR Convergence 2020
Chronic Inflammatory Back Pain Occurring Later in Life: A Neglected Concept
Background/Purpose: Chronic back pain (CBP) is a common musculoskeletal complaint and a significant cause of disability (Weisman et al., 2013). A subset of CBP, chronic…Abstract Number: 1029 • ACR Convergence 2020
Clinical Characteristics of Patients with Axial Spondyloarthritis in China: Results from the ChinaAS Registry
Background/Purpose: The ChinaAS is a nationwide, multicenter registry of patients with axial spondyloarthritis (SpA) in China to facilitate research in epidemiology, pathogenesis, diagnosis and treatment…Abstract Number: 1330 • ACR Convergence 2020
Subclinical atherosclertoic disease in ankylosing spondylitis and non-radiographic axial spondyloarthritis. A multicenter study with 806 patients.
Background/Purpose: Cardiovascular (CV) mortality and morbidity is increased in ankylosing spondylitits (AS) as compared to the general population. Carotid plaque, considered as a surrogate marker…Abstract Number: 1444 • ACR Convergence 2020
Cluster-randomized Pragmatic Clinical Trial Evaluating the Potential Benefit of a Tight-control and Treat-to-target Strategy in Axial Spondyloarthritis: The Results of the TICOSPA Trial
Background/Purpose: Recommendations for axial spondyloarthritis (axSpA) management include tight control and treat-to-target (TC), but no study has evaluated its potential benefit. The objective of this…Abstract Number: 1864 • ACR Convergence 2020
How to Diagnose Axial Spondyloarthritis in 2020? A Data-Driven Estimation of the Disease Probability in Patients with a priori Different Likelihoods of the Diagnosis
Background/Purpose: The diagnosis of axial spondyloarthritis (axSpA) is often delayed by several years and reducing that gap between symptom onset and diagnosis poses a major…Abstract Number: 1890 • ACR Convergence 2020
Daily Management of Patients with Axial Spondyloarthritis: Self-monitoring of Disease Activity with a Smartphone App Is Feasible – a Proof of Concept Study
Background/Purpose: Assessment and monitoring of disease activity and functioning is of major importance for the course of axial spondyloarthritis (axSpA). This is equally important for…Abstract Number: 2021 • ACR Convergence 2020
The Reliability of Scoring Sonographic Entheseal Abnormalities – the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Background/Purpose: DUET is a study supported by the Group for Assessment for Psoriasis and Psoriatic Arthritis (GRAPPA) that aims to develop a novel sonographic scoring…Abstract Number: 0317 • ACR Convergence 2020
Axial Involvement in Psoriatic Arthritis in a Comprehensive Rapid Diagnosis Program (Reuma-check PsA). Analysis of Its Characteristics
Background/Purpose: To date, there is no consensus that allows an appropriate definition of axial involvement in PsA, that ranges between 25 to 70%. To estimate…Abstract Number: 0805 • ACR Convergence 2020
The PROPER Study: Results of the First Interim Analysis of a Pan-EU Real-World Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis
Background/Purpose: SB5, an adalimumab biosimilar received EU marketing authorisation in August 2017, based on the totality of evidence from pre-clinical and clinical Phase I and…Abstract Number: 1031 • ACR Convergence 2020
Real World Treatment Patterns Among Patients with Psoriatic Arthritis Treated with Ixekizumab
Background/Purpose: Psoriatic arthritis (PsA) is a systemic condition estimated to affect 0.05%-0.25% of the United States (US)1 population. With approval of ixekizumab (a selectively binding…Abstract Number: 1333 • ACR Convergence 2020
Ankylosing Spondylitis Patients at Risk of Developing Aortic Valve Regurgitation, Need for Mandatory Echocardiography?
Background/Purpose: The overall mortality rate in ankylosing spondylitis (AS) patients is increased by 60–90% compared with the general population. This higher mortality rate is predominately…Abstract Number: 1518 • ACR Convergence 2020
The Role for Neutrophils in the Early Phases of Enthesitis in Spondyloarthritis
Background/Purpose: Neutrophils are present in the early phases of spondyloarthritis (SpA)-associated uveitis, skin and intestinal disease, but their role in enthesitis remains unknown. We investigated…Abstract Number: 1865 • ACR Convergence 2020
Identification of Parameters Associated with a Diagnostic Delay in Axial Spondyloarthritis:Results from the European Map of Axial Spondyloarthritis (EMAS)
Background/Purpose: Early diagnosis of Axial Spondyloarthritis (axSpA) is crucial for timely access to specialist care and effective treatment. The aim is to assess the current…Abstract Number: 1895 • ACR Convergence 2020
Radiographic Progression in Patients with Axial Spondyloarthritis Under Treatment with TNF Inhibitors. Data from REGISPONSERBIO (Spanish Register of Biological Therapy in Spondyloarthritides)
Background/Purpose: Clinical efficacy of TNF inhibitors (TNFi) in axial spondyloarthritis (axSpA) has been widely probed in randomized control trials. In clinical practice, some studies suggested…
- « Previous Page
- 1
- …
- 33
- 34
- 35
- 36
- 37
- …
- 41
- Next Page »